{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Repaglinide+and+Insulin", "query": { "intervention": "Repaglinide and Insulin" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 5, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T01:37:34.180Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00000620", "title": "Action to Control Cardiovascular Risk in Diabetes (ACCORD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atherosclerosis", "Cardiovascular Diseases", "Hypercholesterolemia", "Hypertension", "Diabetes Mellitus, Type 2", "Diabetes Mellitus", "Coronary Disease" ], "interventions": [ { "name": "Anti-hyperglycemic Agents", "type": "DRUG" }, { "name": "Anti-hypertensive Agents", "type": "DRUG" }, { "name": "Blinded fenofibrate or placebo plus simvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "40 Years to 79 Years" }, "enrollment_count": 10251, "start_date": "1999-09", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2016-11-22", "last_synced_at": "2026-09-24T01:37:34.180Z", "location_count": 6, "location_summary": "Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000620" }, { "nct_id": "NCT03492580", "title": "A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetes Mellitus, Type 2", "Cardiovascular Diseases" ], "interventions": [ { "name": "Canagliflozin", "type": "DRUG" }, { "name": "Empagliflozin", "type": "DRUG" }, { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Dipeptidyl Peptidase-4 (DPP-4) Inhibitors", "type": "DRUG" }, { "name": "Glucagon-like Peptide-1 (GLP-1) Agonist", "type": "DRUG" }, { "name": "Anti-hyperglycemic Agents (AHA)", "type": "DRUG" }, { "name": "Thiazolidinediones (TZD)", "type": "DRUG" }, { "name": "Sulfonylureas (SU)", "type": "DRUG" }, { "name": "Insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 714582, "start_date": "2018-02-22", "completion_date": "2018-06-25", "has_results": false, "last_update_posted_date": "2025-06-25", "last_synced_at": "2026-09-24T01:37:34.180Z", "location_count": 1, "location_summary": "Titusville, New Jersey", "locations": [ { "city": "Titusville", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03492580" }, { "nct_id": "NCT00231192", "title": "Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetes" ], "interventions": [ { "name": "Repaglinide and Insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "12 Years to 20 Years" }, "enrollment_count": 0, "start_date": "2005-10", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2015-03-12", "last_synced_at": "2026-09-24T01:37:34.180Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00231192" }, { "nct_id": "NCT00072904", "title": "Diabetes Therapy to Improve BMI and Lung Function in CF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis", "Diabetes Mellitus" ], "interventions": [ { "name": "Insulin Asparte", "type": "DRUG" }, { "name": "Repaglinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 108, "start_date": "2001-06", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2012-02-28", "last_synced_at": "2026-09-24T01:37:34.180Z", "location_count": 6, "location_summary": "Palo Alto, California • Springfield, Massachusetts • Minneapolis, Minnesota + 3 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Springfield", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00072904" }, { "nct_id": "NCT01798706", "title": "Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Antidiabetic background therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 350, "start_date": "2013-06", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2017-04-18", "last_synced_at": "2026-09-24T01:37:34.180Z", "location_count": 14, "location_summary": "La Jolla, California • Norwalk, California • Miami, Florida + 10 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Norwalk", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01798706" } ] }